2021. Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s63. DOI:https://doi.org/10.25251/skin.5.supp.63.